Featured Research

from universities, journals, and other organizations

No increased risk of suicide in patients using smoking cessation drugs

Date:
October 10, 2013
Source:
University of Bristol
Summary:
A study to assess whether patients prescribed smoking cessation drugs are at an increased risk of suicide, self-harm and treated depression compared with users of nicotine replacement therapy has found no evidence of an increased risk.

A study to assess whether patients prescribed smoking cessation drugs are at an increased risk of suicide, self-harm and treated depression compared with users of nicotine replacement therapy (NRT) has found no evidence of an increased risk. The findings, led by researchers from the University of Bristol, are published online in the British Medical Journal [BMJ] today .

Related Articles


Varenicline (brand name Champix in the UK, Chantix in the US) is widely used by patients seeking to stop smoking with recent figures showing there were one million prescriptions for the drug in England in 2011 alone1. Both varenicline and bupropion (brand name Zyban) -- the other main non-nicotine smoking cessation product -- work by helping to reduce nicotine cravings and withdrawal symptoms. Bupropion is also used to treat depressive illnesses in some countries, but is not licensed for this indication in the UK.

However, concerns that these drugs may increase the risk of suicide have led to safety warnings by regulatory agencies including the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the US Food and Drug Administration (FDA).

Findings from this large-scale study aimed to assess the risk of psychiatric events in patients prescribed varenicline or bupropion compared with those using nicotine replacement products such as patches and gum.

Researchers analysed data from the medical records of 119,546 adults who had used a smoking cessation product between 1 September 2006 and 31 October 2011. Using linked data from the Office for National Statistics (ONS) mortality data and Hospital Episode Statistics (HES), the team were then able to assess the rate of treated depression, self-harm and suicide in 31, 260 (26.2 per cent) patients prescribed varenicline, 6,741 (5.6 per cent) patients prescribed bupropion and compare this with 81, 545 (68.2 per cent) people using nicotine replacement therapies.

The findings, which used three different analytical methods, showed no clear evidence of an increased risk of treated depression or suicidal behavior for patients prescribed with varenicline or bupropion compared to those taking nicotine replacement therapies.

Dr Kyla Thomas, National Institute for Health Research (NIHR) Doctoral Research Fellow and one of the study's lead authors in the University's School of Social and Community Medicine, said: "Given the concerns and accompanying safety warnings for these drugs these findings are reassuring for users and prescribers of smoking cessation medicines."

Professor David Gunnell concluded: "These findings support those of our earlier study2 in a larger, more comprehensive assessment of this important issue; they will be of interest to patients, prescribers and drug regulators."


Story Source:

The above story is based on materials provided by University of Bristol. Note: Materials may be edited for content and length.


Journal Reference:

  1. Thomas et al. Smoking cessation treatment and risk of depression, suicide, and self harm in the Clinical Practice Research Datalink: prospective cohort study. British Medical Journal, October 2013

Cite This Page:

University of Bristol. "No increased risk of suicide in patients using smoking cessation drugs." ScienceDaily. ScienceDaily, 10 October 2013. <www.sciencedaily.com/releases/2013/10/131010205327.htm>.
University of Bristol. (2013, October 10). No increased risk of suicide in patients using smoking cessation drugs. ScienceDaily. Retrieved March 5, 2015 from www.sciencedaily.com/releases/2013/10/131010205327.htm
University of Bristol. "No increased risk of suicide in patients using smoking cessation drugs." ScienceDaily. www.sciencedaily.com/releases/2013/10/131010205327.htm (accessed March 5, 2015).

Share This


More From ScienceDaily



More Mind & Brain News

Thursday, March 5, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Former NFL Players Donate Brains to Science

Former NFL Players Donate Brains to Science

Reuters - US Online Video (Mar. 3, 2015) Super Bowl champions Sidney Rice and Steve Weatherford donate their brains, post-mortem, to scientific research into repetitive brain trauma. Jillian Kitchener reports. Video provided by Reuters
Powered by NewsLook.com
Alzheimer's Protein Plaque Found In 20-Year-Olds

Alzheimer's Protein Plaque Found In 20-Year-Olds

Newsy (Mar. 3, 2015) Researchers found an abnormal protein associated with Alzheimer&apos;s disease in the brains of 20-year-olds. Video provided by Newsy
Powered by NewsLook.com
This Nasal Treatment Could Help Ease Migraine Pain

This Nasal Treatment Could Help Ease Migraine Pain

Newsy (Mar. 2, 2015) Researchers gave lidocaine to 112 patients, and about 88 percent of the subjects said they needed less migraine-relief medicine the next day. Video provided by Newsy
Powered by NewsLook.com
How Facebook Use Can Lead To Depression

How Facebook Use Can Lead To Depression

Newsy (Mar. 1, 2015) Margaret Duffy of the University of Missouri talks about her study on the social network and the envy and depression that Facebook use can cause. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins